Filing Flows › Health Care › Cannapharmarx (CPMD)
Cannapharmarx (CPMD) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 18, 2026 · Cannapharmarx (CPMD) Q2 2026 earnings results →
Q2 2026 Revenue up 19% year over year to $276K · 691¢ of every $1 of revenue lost · operating margin -137.1%
Cannapharmarx made $276K in Q2 2026 (+19% Y/Y). Operating margin -137.1%, net loss $1.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 18, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $276K in Q2 2026, up 19% year over year and down 56% from the previous quarter.
Operating costs exceeded revenue by $379K, an operating margin of -137.1%. Total costs fell 39% while revenue rose 19%. The quarter ended with a net loss of $1.9M, wider than the previous quarter's $382K loss. Net interest and other expense of $1.5M was the main reason.
Operating cash flow was −$127K. Working capital and other items added $1.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 18, 2026 | $276K | +19% | -137.1% | −$1.9M | −$127K |
| Q1 2026 | 10-Q | May 20, 2026 | $627K | +87% | -108.7% | −$382K | −$244K |
| Q4 2025 | 10-K | Mar 31, 2026 | $139K | -71% | -644.6% | −$7.5M | $1.1M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $657K | +110% | -142.5% | −$1.5M | −$803K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $232K | — | -363.1% | −$1.4M | −$446K |
| Q1 2025 | 10-Q | May 16, 2025 | $335K | 13× | -202.1% | −$691K | −$601K |
| Q4 2024 | 10-K | Apr 10, 2025 | $482K | — | -316.9% | −$3.7M | −$180K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Cannapharmarx
CannaPharmaRx, Inc. (“CPMD”, “we”, “our”, or the “Company”) specializes in the acquisition, development, and operation of cannabis cultivation facilities in Canada. Originally incorporated in the state of Colorado in August 1998 as Network Acquisitions, Inc., we evolved to focus on producing high-quality medical cannabis and craft products. Our principal executive office is located at 4439 Township Rd 304, Mountain View County, Alberta, Canada T0M 0R0 and our Internet website address is www.cannapharmarx.com. The information on our website is not incorporated by reference into this annual report.
In its own words, from its 10-K, filed Mar 31, 2026.
Cannapharmarx against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +19% against the peers' median +10%. Operating margin: -137.1% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CPMD Cannapharmarx | Q2 2026 | $276K | +19% | -137.1% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Cannapharmarx 10-Q on SEC EDGAR · CIK 1081938 · Pharmaceutical Preparations
More on CPMD
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results